Furthermore, given the proper matrix, these cellular progenies are also able to selfassemble into a fully functional pseudostratified squamous proximal airway epithelium.
| INTRODUCTION: THE iPSC PROMISE FOR REPAIRING THE CYSTIC FIBROSIS LUNG
Induced pluripotent stem cells (iPSCs) are a recently developed technology in which fully differentiated cells such as fibroblasts can be reprogrammed to resemble the least differentiated embryonic stem cells (ESCs). 1 Subsequently iPSCs can be coaxed to differentiate into pulmonary, cardiac, neural, and other lineages, and finally into fully differentiated cells. 1 Recent studies show that ESCs and iPSCs are genetically identical when developed from the same genetically matched donor cells. 2 Genomic instability in human iPSCs can occur due to replication stress, 3 which can be controlled, for example, by nucleoside supplementation and increases in checkpoint kinase 1 (CHK1). 4 Nonetheless, among the most attractive properties of iPSCs is that they can proliferate rapidly, and can apparently propagate indefinitely. Thus IPSCs can provide large amounts of cells for personalized regeneration of a diseased tissue. This technology thus seems tailor-made for repairing genetic diseases such as cystic fibrosis (CF) in which mutations in the CFTR gene are responsible for a lifelimiting clinical phenotype in the CF lung. [5] [6] [7] Indeed, the timely matching of iPSC and genome editing technologies has recently been described as "forecasting experiments for the next decade." 8 For example, if the [508del]CFTR mutation from a CF patient's iPSCs could be replaced with a [wildtype]CFTR sequence, perhaps using CRISPR/ Cas9 or other editing procedures, 9,10 then the "corrected" iPSCs might be reprogrammed to replace epithelial cells in the diseased lung. This is the ultimate therapeutic promise for iPSC technology.
In vitro, the positive news is that gene editing has been successfully deployed to correct the [508del]CFTR to [wildtype]CFTR in iPSCs derived from a CF patient's fibroblasts. 11 Furthermore, it has been determined that [wildtype]CFTR function and protein can be detected in these now normal cells when they have been differentiated at the air-liquid interface to form proximal airway epithelial cells. 11 As proof of normal function, Firth et al were able to detect cAMPactivated chloride conductance by patch clamp, and mature CFTR protein "C" band by Western blot. CFTR is a cAMP-activated chloride channel, which, when properly glycosylated, trafficks to the apical plasma membrane of epithelial cells as a higher molecular weight "C"
band. Importantly, equivalent experiments have been done by other investigators as well, not only for lung, 12, 13 but also for CF pancreatic duct 14 and CF cholangiocytes. 15, 16 Thus for treating CF lung disease with iPSCs, the vision for this workflow would be as follows: (i) to obtain fibroblasts from a CF patient; (ii) to induce iPSCs from the fibroblasts; (iii) to correct the CFTR mutation, either with CRISPR/Cas9 or zinc-finger nucleases (ZFNs); (iv) to grow up unlimited numbers of corrected iPSCs; and (v) to induce iPSCs to differentiate; and (vi) to deploy them back into the CF patient who donated the original fibroblast as personalized medicine. However, as we shall see below, the deployment part of this algorithm remains a significant challenge.
By focusing attention on the CF airway, a second profound challenge is understanding exactly what histological structures are being reconstituted, by which cells, and in which order. Which are the cells to which the iPSCs should be induced to develop, and how pure must the iPSCs and their induced progeny be? To develop iPSCs into therapies, should we be trying to use fetal development of the lung as a roadmap for repair and reconstitution, or is there another way? A final question is how to "administer" the iPSC-based therapy. Suggestions have ranged from whether to introduce cells as individuals or as pregrown sheets of mature endothelium through the airway; or to re-seed bronchi and bronchioles that have been stripped of mutant epithelium;
or to inject the spheroids of mature lung cells of cadaveric origin intravenously, and let them spontaneously find their way to the lung. 17 However, there are clinical, structural, and physiologic barriers which must be overcome to move from these in vitro proof-ofprinciple experiments to deploying the technology therapeutically in CF patients. Many outstanding articles and comprehensive reviews have been published in the last few years that specifically address the lung. [18] [19] [20] [21] [22] Here, we will assess important challenges that the lung, and the CF disease itself, erects against different therapeutic strategies. In addition, there is much more to cystic fibrosis than the effects on the lung. We will discuss this aspect of CF below. Yet it is in the lung where the threat-to-life is most manifest, and where clinical work-arounds have been most challenging. We, therefore, focus primary attention in this review on replacing CF epithelial cells lining the CF airway, and on the challenges of the present state of the science. On a positive note, it has been calculated that by delivering just 25% of wildtype CFTR to the CF epithelial surface one might observe normal rates of mucus transport on the CF epithelium. 23 This calculation would thus seem to set a lower limit to the kind of success that added iPSCs might bring to a The physiology of the CF lung seems to be focused on failure of the cAMP-activated CFTR chloride channel to secrete chloride into the airway, with consequent dehydration of the airway. 24 If the channel had been active, first sodium and then water would have followed the chloride, and hydration of the airway would have been assured. The consequences of failure are catastrophic, especially when concatenated with the concomitant failure of the airway epithelial cells to discriminate between septic bacterial and viral infection, and aseptic damage such as dehydration, free neutrophil elastase, or an acidic environment. Thus in response to a damage stimulus, the CF goblet cells secrete mucus into a dehydrated airway. However, secreting mucus into a dehydrated environment limits mucin distribution, and results in thick, sticky mucus. Physiologically, this makes sense to the body because the function of the mucus is to protect airway cells by binding to bacteria and viruses. Therefore, on the explicit assumption that microbial invaders have arrived, and that there is a need to deflect them from their intended epithelial cell targets, mucus will be available to bind them. The ciliary cells will then ferry the mucin-bound microbes up and out of the lung. But because the CF POLLARD AND POLLARD | S13
airways are poorly hydrated, the mucus, along with the invaders stuck to it, becomes immobilized within the airway. 25 This leads to failure of mucociliary clearance, especially in the small airways that are denied air due to being blocked off by mucin plugs. 26 These are now sites of potential infection. Impaired PGE2-stimulated chloride and bicarbonate secretion in submucosal glands also contribute to cystic fibrosis airway disease. 27 The importance of bicarbonate is further manifest by a recent report of data from the CF rat, in which correction of low pH and bicarbonate transport is a specific target for restoring mucus clearance. 28 Further regarding oxygen detection in mucin-blocked airways, neurosecretory cells at bronchial bifurcations signal to the brain through their vagal nerve innervation that CO 2 levels are high and O 2 levels are low. Vagal innervation which contributes to the cough reflex in humans, 29 may be very important to the CF patient for helping clear blocked airways. 30 In the hypoxic mutant CFTR condition, it has been shown that hypoxia-induced 5HT (serotonin) release from neuroendocrine cells is likely suppressed, as well as the secretory response to high potassium. 31 In conclusion, even if immune cells do respond by entering into mucin-blocked, low oxygen regions, they do not function well in an environment that is additionally low in chloride because of mutant CFTR, and low in pH because of low bicarbonate.
Bacteria and viruses can then grow in these mucin plug blocked places where infection is further enhanced by denial of access to blood-born
antibiotics. An important target for iPSC-based CF therapies would therefore be either suppression of mucin production or increased hydration, or both, in the CF submucosal glands and airways.
| Inflammation
CF airway epithelial cells chronically secrete high levels of chemokines such as IL-8 and cytokines such as IL-6, IL-1β, and TNFα. [32] [33] [34] The tendency to secrete high levels of IL-8 occurs under both baseline and activated conditions. The causative mechanism in CF is based on an intrinsically constitutive activation of NFκB signaling. CFTR can suppress these constitutive chemokine and cytokine elevations. 33 Thus, suppression of the hyper-proinflammatory CF phenotype in the lung will be a necessary target for lung-centric iPSC-based therapies.
| Immune cell dysfunction
A third lung-centric CF problem is that CFTR mutations affect immune cell functioning. Examples include neutrophils, 43 macrophages, 44 Although the mechanism is unknown, there is a well known clinical phenomenon connecting inflammation in the pancreas with pulmonary inflammation. 72 Thus pathology in these separate organs are linked in some manner, possibly by the shared vagus nerve.
Other systems sensitive to CFTR function include the male urogenital system, where congenital hypoplasia or aplasia of the vas deferens and seminal vesicles may occur either bilaterally or unilaterally. 73 Consequently, most CF males are phenotypically sterile.
Finally, in skin, the dysfunction of the sweat glands is life-threatening in hot, humid weather, and is patho-mnemonic for CF. 74, 75 Mechanistically, mutant CFTR prevents the sweat glands from reabsorbing chloride. However, while these non-lung centric CF cell disorders remain unresolved, most would agree that the central threat to life for the CF patient lies squarely in the cells lining the proximal airway. these cells comes from the mouse, where possible most investigators have been careful to test for parallels between mouse and humans.
Remarkably and fortunately, the parallels have proved to be quite substantial.
| Proximal airway development, in vivo and in vitro
During fetal development in mouse and human, the foregut endoderm begins to form lung buds, which further undergo stereotypical branching morphogenesis. 19 The initial epithelium is composed of proximal progenitors, including basal cells, which closely adhere to the basal lamina. Basal cells have been presumed to be the stem cells for the rest of the pulmonary epithelium, based on studies dating back more than 25 years, [76] [77] [78] and more recently shown definitively. 79 The 
| Basal stem cell differentiation
Consistent with the data from Rock et al 79 and as summarized in Figure 1A , the basal stem cells are able to differentiate into club cells, increased NOTCH signaling. 80 In both mouse and human, club cell differentiation into goblet cells is also accompanied by SPDEF and FOXA3 expression following allergen exposure. 83 Finally, intermittent de-programming has been applied to club cells to generate a less differentiated state with the classical four component cocktail consisting of: Oct3/4, Sox2, Klf4, C-Myc. 84 The result is rapid expansion of a cell population that can be redifferentiated with 50%
efficiency in vitro to a large club cell population. This redifferentiated club cell population can be used to repopulate denuded tracheal tissue in vivo, or in vitro at the air liquid interface, to yield a totally reconstituted epithelial surface, complete with apical expression of CFTR.
| Submucosal glands
Submucosal glands are found in the trachea in mouse, and in both the trachea and many generations of bronchiolar bifurcations in the human lung. 85 These glands are the result of substantial in-pocketing of the airway surface epithelium, which has the effect of vastly increasing surface area of the lung. It has been appreciated for many years that progenitor cells of the adult human airway contribute to submucosal gland development. 86 In the case of CF, where mucus is thickened, and clearance is profoundly compromised, the ducts connecting the submucosal glands to the airway surface epithelium are blocked by thickened mucus. Thus, it has been readily appreciated that cells in the submucosal glands may not have efficient access to medicinal agents administered to the airway, if the agent cannot easily navigate through mucin-blocked ducts. In fact, the basal stem cells in the submucosal glands are in a specialized niche, 87 where they are protected from toxic inhaled gases, particulates and microorganisms, and thus serve as a reserve to repopulate the airway epithelium. 88 exchange. The transition between the proximal and distal airways may differ in some detail between mouse and human, so this is an area of lung biology that is still not fully understood. 87 Importantly there is little evidence that gas exchange, per se, is a critical problem for the CF patient. However, as further summarized in Figure 1B, 
| iPSCs TO RESCUE CF LUNG DISEASE
As shown in Figure 2A -E, it has become possible to isolate iPSCs from a CF patient, convert the CFTR mutation to the wildtype Cells by a medium including retinoic acid (RA) (Figures 2C and 2G ), or lung endoderm ( Figures 2C and 2D) Additional progress was also made in terms of increasing the efficiency of these development pathways by Mou et al, 99 who used a similar differentiation protocol, but differently timed, on both mouse and human iPSCs. Remarkably, these investigators showed that mouse and human progenitors were able to form respiratory epithelium in situ when injected subcutaneously in nude mouse models. Because NKX2.1 is also known as thyroid transcription factor-1, Longmire et al 100 were motivated to find a way to able to separately purify lung and thyroid NKX2.1 progenitors. They did so by inclusion of FGF2 in the differentiation medium (see Figures 2B and 2C ). These pathways details are for the most part still definitive, 19 although significant progress in increasing efficiency has been accomplished. 95 Thus with preparations of basal stem cells in hand, it has now become possible to ask personalized questions regarding the metaplastic properties of the iPSC-derived calls, and to compare the results with data inferred from experiments with naturally abundant basal stem cells.
| Human lung organoids (HLOs) in 3-D culture
A perceived limitation of the iPSC approach to therapy is that directed differentiation of iPSCs do not lead to a complete lung. other drug regimens. In prospect, it would appear that the study of specific drug actions on these personalized iPSC-derived CF epithelial cells will be critical in both understanding patient-specific disease progression for different CFTR mutations, and in developing the best drug treatments for individual patients.
The concept of developing "lab-on-a-chip"(LOC) technology for CF has only recently begun to mature. [103] [104] [105] A LOC is a microfluidics device that integrates several laboratory functions on a single integrated circuit to achieve automation and high throughput. 106 For our present purposes, however, "lab-on-a-chip" has become "lungon-a-chip," in which cyclic mechanical stress can be applied to either proximal or distal lung epithelial cells. For example, it has been possible to mimic what might be happening in emphysema, where wall stresses might be great, 107 or ventilator-induced lung injury, where flow and stretch conditions can vary profoundly from normal states. 108 In pre-"lung on a chip" era studies on cyclic stretch effects on lung cells, it was found that stretch (15% strain for 4 h at 20 cycles/min), as induced by a ventilator-induced lung injury, could affect both glutathione biochemistry and secretion of IL-6 and IL-8 in the adenocarcinoma A 549 cell model of Type II Alveolar Cells. 109 Another early study in the same cell system showed that cyclic stretch could not only enhance proliferation, but also mitigate the detrimental effect of hypoxia on cell proliferation and viability. 110 However, Figure 3A -E demonstrates properties of a more recently developed sophisticated lung-on-a-chip," constructed by Guenat and coworkers, that is possibly more CF-relevant. 111 Figure 3A shows how a bioartificial alveolar membrane can be induced to stretch by a microdiaphragm, which is itself actuated by an electro-pneumatic driver. Figure 3B is a schematic for a triple "lung-on-a-chip," which consists of three microfluidic cell culture wells, each identical to the units described in Figure 3A . Figure 3C shows the actual physical assembly in which the lower chambers are filled with food dye for greater visibility. Figure 3D shows the xy-projection from a confocal microscope image of a confluent monolayer of normal human bronchial epithelial cells (16HBE14o-), growing as a monolayer on platform could therefore provide a complete way to study drug effects and lung biology for individual CF patients, especially patients with the less common CFTR2 mutations. [112] [113] [114] [115] Relevantly, tidal breathing has been shown to affect phasic motion-induced shear, with consequences for release of nucleotides to the extracellular space and regulation of pericellular liquid homeostasis in CF patients. 116 The lung-on-a-chip concept also permits a more global physiological view of CF, in which the disease is more than just a CFTR mutation. Rather it provides a more physiologically relevant context for analysis. 117 
| Replacement of mutant lung cells by wildtype lung cells in the living lung
The so-far unresolved challenge has been how to use the iPSC technology for therapy: the replacement of mutant lung epithelial cells with their wildtype equivalents. We give several examples here to illustrate that this approach has been tested in different ways, and for different indications. One approach has been to attempt to perform the replacement in the otherwise diseased but still functional lung. One strategy has been to administer iPSCs directly by the intravenous route. [118] [119] [120] For example, acute lung injury (ALI) was induced in mice by administering endotoxin by the endotracheal route. 118 Mouse iPSC cells were then delivered into the mouse by tail vein injection. The consequences were that iPSC incorporation was enhanced; histopathologic changes, NFκB and neutrophil accumulations were reduced; and hypoxemia and pulmonary function were rescued. In these cases, iPSCs were apparently being used as a drug. In another strategy, immuno-competent mice, that had been treated with bleomycin to induce a model of interstitial fibrosis, were injected with cultured allogeneic and syngeneic adult lung spheroids. 17 Progression of fibrosis and inflammation were suppressed, without eliciting significant immune rejection. A human trial is said to be planned. In an alternative to the intravenous injection route, lungs of mice and pigs, whose lungs had been pre-injured/pre-conditioned with 2% polidocanol (PDOC), mature human airway epithelial cells were administered intra-tracheally. 121 Based on a fluorescent label, cell retention/ "engraftment" 2 days later was ca. 10% in mouse and ca. 22% in the pig. The purpose of the PDOC, an FDA-approved local anesthetic and anti-pruritic, was to temporarily remove the surface airway epithelial cells, thereby opening up a place for epithelial cell engraftment, and activating proliferation of normally quiescent epithelial cells by enhancing cytokine and chemokine expression in the airway.
The "pre-injured/pre-conditioned strategy" has also been attempted in studies with direct CF-centric relevance. 
| Decellularized lungs and artificial scaffolds
In response to the fact that there are so few lungs available for transplant, and so many patients in need, the idea of artificial lungs has developed significant appeal. 124, 125 One more recent CF-relevant idea has been to use a patient's corrected iPSCs to repopulate a decellularized lung, and then to replace the diseased lung with the re-cellularized lung. The object of studies on lungs, ranging from mouse 126 to a non-human primate (Rhesus macaque), 127 has been to isolate an intact scaffold made up of a passive extracellular matrix, which can be repopulated with autologous stem or progenitor cells. progenitor cells bound to the scaffold surface and differentiated into mature airway epithelia, including ciliated cells (FOXJ1+, TUBB4A+), club cells (SCGB1A1+), and basal cells (TRP63+, KRT5+). CFTR protein was present, and was also functional, as defined by cAMP-dependent iodide efflux. Pit-like structures upon the surface could be discerned by optical microscopy. These were interpreted as nascent submucosal glands, and confirmed by scanning EM. Importantly, the epithelial differentiation process proved to be dependent upon the presence of heparinase I-sensitive heparin sulfate proteoglycans in the decellularized matrix. This paper also emphasized an important control: showing that decellurized kidney sections, a mesoderm-derived tissue, could not replace decellularized lung sections as a matrix for constitution of the airway epithelium. Thus this heavily washed and fixed scaffold is still biochemically "alive." Nonetheless, the lung physiologist reading this will think of many more organismic properties that this bioengineered lung must display in order to be durable and operational.
| CONCLUSION
Based on the state of the science, it appears that the best use of iPSCs for CF lies in using them from individual CF patients in their differentiated states for personalized medicine. For example, the impact of different bystander/modifier genes on drug responses can be studied today using a lung-on-a-chip approach. Thus the ability of specific variants in a patient's bystander/modifier genes can be assessed in terms of how a specific drug might affect CFTR trafficking and CFTR function, including cAMP-activated chloride transport or inflammation. However, in thinking of using iPSCs to create a durable physical therapy for CF lung disease, we quote the opinion of Shinya Yamanaka, the 2012 Nobel
Laureate for the development of the iPSC technology, who concluded that "the potential is enormous, but many obstacles remain before this technology can become converted to therapy." TUBB4A: Tubulin beta-4A. TUBB4A is a form of tubulin (TUB), a major cytoskeletal protein, which together with TUBB4B is said to be preferentially and highly expressed in the central nervous system. Curiously, it is also a biomarker for ciliated cells.
UCHL1: ubiquitin carboxy-terminal hydrolase L1. UCHL1 is mostly found in the brain and testes/ovary. However, it is also found in lung and is a biomarker for neuroendocrine cells. 
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